A Phase 2/3 interventional study of Dietary Caffeine Intake in Atrial Fibrillation (AF), Permanent Atrial Fibrillation and Coffee Consumption, sponsored by Hospital Universitario Getafe. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Hospital Universitario Getafe · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 247 studies in Atrial Fibrillation with a site in Spain — 53 open to participants now, 76 under way, 3 of them phase 3. Atrial Fibrillation · Spain.
Among the 247 studies in Atrial Fibrillation with a site in Spain, this one is the 148th largest by planned enrollment of the 162 interventional ones that give a count, is one of 10 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 56 of the 75 other live ones, and was the 245th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →53 of the 247 studies in Atrial Fibrillation with a site in Spain are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain, Belgium, Germany and 3 more countries
Ages 18+
Boston Scientific Corporation · Sites in Spain, United States, Belgium and 1 more country
Ages 18+
Boston Scientific Corporation · Sites in Spain, Belgium, Croatia and 2 more countries
Ages 18+
Abbott Medical Devices · Sites in Spain, Belgium, Czechia and 7 more countries
Ages 18+
Hospital Clinic of Barcelona · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
247 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 37 · Phase 4 27
First in 2001; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 304 across the 162 interventional studies, 500 across the 85 observational. Of the 154 that completed or were terminated, 60 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 247 have an industry lead sponsor. The 10 most frequent:
Hospital Universitario Getafe is the lead sponsor of 29 studies on the registry; 3 are open to participants now.
Hospital Universitario Getafe has 2 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
24 of the studies in Atrial Fibrillation with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07598903Centro de Emergencias Sanitarias 061 AndalucíaPharmacy-based Opportunistic Atrial Fibrillation Screening Integrated With Emergency Services (NUMAPLUS-FA) | 2026-12-15 |
| NCT07339007Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC)Observational Study to Validate a Family Physician Echocardiography Training Programme | 2026-12-31 |
| NCT07358611Hospital Clinic of BarcelonaNon-invasive Mapping-Guided Atrial Fibrillation Ablation | 2026-12-31 |
| NCT07390175Hospital San Carlos, MadridAblation of Human Cardiac Fibrillation Based on Models of Hierarchical Organization of Tissue Excitation | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 247 studies in Atrial Fibrillation with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The CAFIB trial is a multicenter, randomized, open-label, crossover clinical trial designed to determine whether habitual caffeine consumption in coffe adversely affects rate control in patients with permanent atrial fibrillation (AF).
The rationale stems from the discrepancy between traditional clinical recommendations, which often advise patients with arrhythmias to avoid caffeine, and the growing body of evidence suggesting that moderate coffee consumption is not associated with an increased risk of AF and may even confer cardiovascular benefits. However, no randomized study has specifically investigated this issue in patients with permanent AF, a population in whom rate control remains the cornerstone of management.
The primary hypothesis is that continued moderate caffeine consumption is non-inferior to caffeine abstinence regarding 24-hour mean heart rate control.
Participants will be randomly assigned in a 1:1 ratio to one of two treatment sequences stratified according to baseline coffee intake (1 cup/day vs. >1 cup/day). Owing to the nature of the intervention, the study is open-label; nevertheless, Holter recordings will be analyzed by blinded investigators, and the statistical analysis will also be performed blinded to treatment allocation to minimize bias.
Eligible participants are adults with permanent AF diagnosed for more than three months, stable ventricular rate control (\<110 bpm at rest), unchanged rate-control medication for at least two months, and habitual coffee consumption of at least one caffeinated cup per day. Patients with advanced heart failure, recent major cardiovascular events, cognitive impairment, implanted cardiac pacing devices, or other conditions likely to interfere with study outcomes are excluded.
The intervention compares two dietary strategies: continuation of regular caffeinated coffee consumption (at least one cup daily) versus complete caffeine abstinence, while allowing decaffeinated coffee. Energy drinks are prohibited in both groups, and participants assigned to abstinence are advised to avoid compensatory caffeine intake from other sources. No washout period is planned between crossover phases because caffeine has a biological half-life of less than 24 hours. Adherence will be assessed using caffeine consumption diaries and structured interviews at each study visit.
The primary endpoint s the 24-hour mean heart rate measured by ambulatory Holter electrocardiography. Secondary endpoints include changes in mean HR from baseline, percentage of time with HR >110 bpm or \<50 bpm, ventricular ectopic burden, symptom severity assessed using the modified EHRA classification, quality of life evaluated with the AFEQT questionnaire, circulating biomarkers of heart failure, adverse events, and changes in concomitant medical therapy.
Patients will undergo three scheduled visits (baseline, 30 days, and 60 days), each including clinical assessment, ECG, 24-hour Holter monitoring, blood sampling, and quality-of-life questionnaires.
Sample size calculation was based on detecting a clinically relevant difference of 5 bpm, assuming a standard deviation of 7 bpm, 80% statistical power, and a two-sided α of 0.05. After accounting for an anticipated 25% dropout rate and potential protocol deviations, a total of 50 patients (25 per treatment sequence) will be recruited. The primary analysis will follow the intention-to-treat principle, complemented by a per-protocol analysis. Statistical models will adjust for clinically relevant covariates, including age, sex, baseline heart rate, and concomitant rate-control therapy, while multivariable regression analyses will explore predictors of optimal heart rate control.
The protocol acknowledges several limitations, including its open-label design, reliance on self-reported caffeine intake to assess adherence, interindividual variability in caffeine metabolism, and limited external validity to stable, habitual coffee consumers with permanent AF. Despite these limitations, CAFIB represents the first randomized trial specifically evaluating the impact of caffeine consumption on ventricular rate control in permanent AF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will continue with their usual caffeine intake. Energy drinks intakes are prohibited.
Dietary Supplement: Dietary Caffeine Intake
Complete caffeine abstinence, while allowing decaffeinated coffee. Energy drinks are prohibited.
Patients will mantain their usual caffeine consumption
Mean Heart Rate (bpm)
Mean Heart Rate (bpm) in 24-h Holter-ECG
Time frame: 30 ± 5 days
Difference with baseline heart rate
Mean difference between baseline and follow up heart rate (bpm)
Time frame: 30 ± 5 days
Symptoms Asessment
Changes in Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire. Scores ranged 0-100. 0 represents the worst quality of life and 100 the best.
Time frame: 30 ± 5 days
Adverse Events
Incidence of new emergency department visit due to atrial fibrillation, heart failure, acute coronary syndrome, stroke or systemic embolism.
Time frame: 30 ± 5 days
Changes in rate-control medication
Changes in rate-control medication (including betablockers, calcium channel blockers, digoxin or amiodarone)
Time frame: 30 ± 5 days
Premature Ventricular contraction burden
Absolute and relative (%) burden of premature ventricular contractions in 24-h Holter-ECG
Time frame: 30 ± 5 days
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Dec 2027, 17 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitario Getafe